Key Takeaways
- UNH started trading at $277.32, significantly below its 52-week peak of $606.36
- Wall Street firms reduced targets — JPMorgan to $389, Truist to $370, UBS to $410
- Weiss Ratings issued a Sell rating for UNH in early March
- Q4 earnings per share of $2.11 exceeded estimates slightly; revenue increased 12.3% to $113.73 billion
- Analyst consensus still shows Moderate Buy with $372.13 average price target
UnitedHealth Group (UNH) has experienced significant turbulence in recent months. The healthcare giant’s shares opened at $277.32 Monday morning, trading substantially below both the 50-day moving average of $297.19 and the 200-day moving average of $324.39.
This represents a dramatic decline from the stock’s 52-week high of $606.36. The 52-week low stands at $234.60.
The healthcare conglomerate currently maintains a market capitalization of $251.71 billion, trading at a price-to-earnings ratio of 21.02 with a beta of 0.41.
UNH carries a debt-to-equity ratio of 0.72, while both the current ratio and quick ratio register at 0.79.
During January, UnitedHealth disclosed Q4 earnings of $2.11 per share, marginally surpassing the consensus forecast of $2.09. Revenue reached $113.73 billion, representing a 12.3% year-over-year increase and edging past analyst projections.
However, the Q4 EPS figure represents a substantial decline from the $6.81 posted during the identical quarter one year prior.
Wall Street Reduces Price Expectations
Numerous prominent financial institutions have reduced their price projections in recent weeks.
JPMorgan decreased its target from $425 down to $389, Morgan Stanley adjusted downward from $411 to $409, and UBS lowered its projection from $430 to $410. Truist executed the most aggressive reduction, dropping from $410 to $370. Despite these cuts, all four firms retained Buy or Overweight recommendations.
Weiss Ratings took a more bearish stance, downgrading UNH from Hold to Sell during early March.
MarketBeat’s current consensus rating stands at Moderate Buy, incorporating 17 Buy ratings, 8 Hold ratings, and 2 Sell ratings. The average 12-month price target of $372.13 suggests approximately 34% potential upside from present levels.
Institutional investors have shown mixed activity. Wealth Enhancement Advisory Services reduced its position by 40.6% during Q4, divesting 170,643 shares. Conversely, Norges Bank, Berkshire Hathaway, and Capital Research Global Investors either expanded or initiated positions throughout 2024. Institutional ownership represents 87.86% of outstanding shares.
Regulatory Challenges Persist
Department of Justice investigations surrounding Medicare Advantage reimbursement methodologies continue to impact investor sentiment. While the company has secured at least one favorable legal outcome in that matter, broader regulatory scrutiny regarding prior-authorization procedures and coverage denial policies remains active.
Executive leadership has previously disclosed intentions to reduce certain Medicare Advantage membership and adjust pricing strategies in response to changing cost dynamics.
The company issued FY2026 EPS guidance of approximately $17.75. Wall Street analysts currently forecast full-year EPS of $29.54 for the ongoing fiscal year.
UNH distributed a quarterly dividend of $2.21 per share on March 17, yielding approximately 3.2% on an annualized basis. The current payout ratio sits at 67.02%.
On a more optimistic note, UnitedHealth recently unveiled a nationwide expansion of its doula benefit program, which may enhance member retention and strengthen results within its value-based care framework.
